Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00139672 | A Study To Investigate The Effect Of PD-217,014 On Abdominal Pain/Discomfort In Patients With IBS. | PHASE2 | COMPLETED | 330 | — | — | Jan 1, 2004 | Feb 1, 2005 | Jun 17, 2008 | - | — |
| Name | Type | Description |
|---|---|---|
| PD-217,014 | DRUG | - |
Inclusion Criteria: * Males and females having Irritable bowel syndrome as defined by the Rome II criteria. * Patients must have had normal examination of colon anatomy within the last 5 years Exclusion Criteria: * Patient with an organic gastrointestinal disease. * Patients with poor renal funct...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Ardelyx, Inc. | ARDX | 4 | PHASE3 | Tenapanor |
| AbbVie, Inc. | ABBV | 2 | PHASE3 | Eluxadoline |
| Disc Medicine, Inc. | IRON | 1 | PHASE2 | DISC-0974 |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 2 | — | Undisclosed |
| Johnson & Johnson | JNJ | 1 | — | Anti TNF therapy including infliximab, No Biologics |
| Cooper Companies, Inc. | COO | 1 | NA | Undisclosed |